Butifen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Butifen

Property Description
Active ingredient Ibuprofen (INN)
Form Tablet, capsule, suspension (Oral)
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Pain, Fever, and Inflammation relief
Origin Synthetic, Propionic acid derivative

What Type of Medicine is Butifen? (Identity and Classification)

Butifen is a synthetic pharmaceutical preparation whose active ingredient is Ibuprofen (INN). The medication is defined as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a class of compounds utilized for efficacy in symptom management.

As an NSAID, the preparation's fundamental identity is rooted in its three primary actions: serving as an analgesic for pain relief, an antipyretic for fever reduction, and possessing definitive anti-inflammatory capabilities. Ibuprofen is clinically recognized for its ability to moderate these symptoms, which encompasses the essential, concurrent management of typical inflammatory and feverish discomfort.

Butifen's Composition and Origin: A Synthetic Propionic Acid Derivative

The chemical composition of Butifen centers on the synthetic compound Ibuprofen, which belongs chemically to the propionic acid derivative subclass. The product is commonly available as a single-ingredient formulation and is designed for the oral route of administration in several oral dosage forms, including the tablet, capsule, and liquid suspension.

A key characteristic is the typical supply of the ingredient as a racemic mixture containing both the active S-enantiomer and the R-enantiomer, which the body converts into the active form. This structural feature supports the official classification of the active substance as a Cyclooxygenase Inhibitor.

General Purpose: Relieving Pain, Fever, and Inflammation

The general therapeutic purpose of Butifen is to mitigate physical discomfort by targeting the underlying biological processes that cause pain, fever, and inflammation. Its physiological action is based on the reversible inhibition of cyclooxygenase (COX) enzymes.

By interfering with these enzymes, the preparation temporarily slows the body's production of prostaglandins—the chemical mediators responsible for transmitting pain signals and triggering inflammatory reactions. This mechanism allows Butifen to effectively exert its triple function, providing general relief in situations characterized by elevated body temperature and localized inflammatory symptoms.

What side effects are possible with Butifen?

Possible Side Effects and Safety Information

The safety profile for Butifen, whose active ingredient is Ibuprofen, is defined by formal classifications and warnings documented in governmental regulatory sources.

Adverse reactions are formally grouped by the body system affected and assigned frequency categories such as Common (e.g., gastrointestinal disturbances, headache) and Uncommon (e.g., hypersensitivity reactions). The primary body systems involved, as classified in official documentation, include Gastrointestinal Disorders, Nervous System Disorders, and Renal and Urinary Disorders.

Regulatory agencies consistently highlight two major categories of Serious Adverse Reactions. These include Serious Gastrointestinal Events, such as bleeding, ulceration, and perforation, and Serious Cardiovascular Thrombotic Events, including the risk of Myocardial Infarction and Stroke. Official labeling specifies that the risk of these serious events may increase with longer duration of use and higher doses.

Population-specific safety considerations state that Older Adults have an officially recognized increased risk for serious adverse events, particularly severe gastrointestinal bleeding. The medication is contraindicated for the treatment of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with known hypersensitivity to NSAIDs. The regulatory safety framework ensures that the full spectrum of potential risks is communicated in a structured, non-advisory format.

Overdose and Emergency Response

Butifen Overdose and when to seek help

The official regulatory profile for Butifen (Ibuprofen) defines the manifestations and required emergency actions strictly based on documented clinical experience.

Documented Overdose Presentations:

Classification Manifestations and Signs
Common Nausea, vomiting, epigastric pain, headache, drowsiness, dizziness, tinnitus, and blurred vision.
Severe / Life-Threatening Acute renal failure, metabolic acidosis, severe hypotension, gastrointestinal bleeding or perforation, and severe CNS depression leading to coma or seizures.

Emergency Actions Mandated by Regulators:

Government health authorities require individuals to seek immediate medical attention or contact a poison control center upon any suspected overdose. Immediate help is required when severe manifestations, such as breathing difficulties, seizures, loss of consciousness, or signs of organ compromise, are present.

Management is defined as symptomatic and supportive treatment, as no specific antidote is known. Procedural steps described in regulatory sources for recent ingestion may include gastric lavage or administration of oral activated charcoal. Hospital observation is necessary, including continuous monitoring of vital signs, renal function, hepatic function, and electrolytes.

Population-Specific Notes: Elderly patients carry an increased risk for serious gastrointestinal events. In children, ingestions of specific high quantities (e.g., 400 mg/kg or more) are associated with greater risk for developing severe toxicity.

Therapeutic Uses of Butifen

What Butifen Treats: Main Uses and Benefits

Butifen (Ibuprofen) is commonly used to help with symptomatic relief across key therapeutic domains where acute discomfort, inflammation, or fever create noticeable interference with daily stability. It may be part of symptomatic management, offering supportive relief that helps patients cope more steadily with difficult episodes. The main use of its active ingredient is to help relieve minor aches, pains, and reduce fever.


Key Therapeutic Applications

Butifen is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states. It is relevant for easing challenging symptoms of conditions associated with the common cold, flu, and minor soft tissue injuries. Specifically, it is used for managing pain from tension headaches, toothaches, muscular aches, and the spasmodic symptoms of menstrual cramps.

“The role of this medication is generally to provide supportive relief, which may help ease distress and contribute to day-to-day comfort during symptomatic periods.”

Benefits and Symptom Management

The medication is commonly used when short-term symptomatic assistance is needed to address symptom clusters of swelling, tenderness, joint stiffness, body aches, and malaise. It is relevant for managing the symptoms of minor pain of arthritis and is applied in addressing elevated body temperature (fever). By helping to reduce these manifestations, Butifen provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Acute, Mild-to-Moderate Pain and Fever
Applied in contexts involving temporary physiological imbalance and symptomatic discomfort.

Eligibility and Restrictions for Use

Butifen (Ibuprofen) is subject to strict eligibility rules based on regulatory labeling. Use is contraindicated and absolutely prohibited for specific patient populations.

Cannot Use (Contraindicated) Basis for Non-Eligibility
Known Hypersensitivity Allergy to Ibuprofen, Aspirin, or other NSAIDs.
Severe Organ Failure Severe heart failure (NYHA Class IV), renal, or hepatic failure.
Bleeding/Ulcers Active or history of recurrent gastrointestinal bleeding or peptic ulcers.
Pregnancy Third trimester of pregnancy (30 weeks gestation and later).
Surgery Pain treatment following Coronary Artery Bypass Graft (CABG) surgery.

Eligibility is also determined by age and comorbidity status. The medicine is approved for adults, teenagers, and children aged 6 months and older for general use, but its safety is not established for infants younger than 6 months. Special caution and monitoring are required for older adults (60+) due to increased risks. For patients with cardiovascular risk factors (e.g., uncontrolled hypertension) or non-severe renal or hepatic impairment, use is restricted and should be limited to the lowest effective dose. Ibuprofen is generally considered compatible with breastfeeding, but it is not recommended during the first and second trimesters of pregnancy.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Butifen (Ibuprofen) has documented interaction patterns primarily involving pharmacodynamic risk enhancement and pharmacokinetic exposure modification, as defined by regulatory agencies. Co-administration with certain agents is strictly constrained.

Official Interaction Statements

Interacting Substance/Class Official Interaction Pattern/Outcome
Other NSAIDs or High-Dose Aspirin Contraindicated due to increased risk of gastrointestinal ulceration and bleeding.
Anticoagulants (e.g., Warfarin) Enhances the risk of gastrointestinal and other bleeding events.
Oral Corticosteroids / SSRIs Increased documented risk of gastrointestinal ulceration and bleeding.
Lithium or Methotrexate Reduces the renal clearance of these agents, resulting in increased plasma concentrations.
Antihypertensives (e.g., ACE inhibitors) May reduce the therapeutic effect of these medications.
Alcohol (Ethanol) Documented to increase the risk of gastrointestinal bleeding.

For low-dose Aspirin used for cardioprotection, immediate-release Butifen must not be administered within 8 hours before or 30 minutes after the aspirin dose to avoid interference with its antiplatelet effect. The medication is also contraindicated for treating peri-operative pain during CABG surgery, and risks are heightened in elderly patients and those with severe organ failure.

Mechanism of Action

How Butifen Works

Butifen (Ibuprofen) exerts its action entirely through a process of non-selective enzyme inhibition, which alters the regulation of the Arachidonic Acid Cascade at a molecular level.


Modulating the Prostaglandin Synthesis Cascade

The molecule operates by reversibly blocking the active sites of the Cyclooxygenase (COX) enzymes, specifically both the COX-1 and COX-2 isoforms. This molecular interference blocks the generation of the precursor Prostaglandin H2 ( PGH2) that would otherwise initiate the downstream cascade of physiological changes. This interruption prevents the subsequent formation of various prostaglandins—the chemical mediators that modulate nerve signaling and inflammatory processes.


Regulation of Nociceptive and Thermoregulatory Responses

The resulting reduction in prostaglandin levels directly influences two major physiological systems. In the periphery, lower levels of PGE2 and PGI2 lead to a decreased excitability of nociceptors (pain-sensing nerves). Simultaneously, a similar reduction of PGE2 in the hypothalamus causes a reduction in the elevated temperature set-point. These concurrent peripheral and central effects result in a measurable alteration of key physiological responses.

Dosage and Administration Information

Official Administration Protocol

Butifen (Ibuprofen) is approved for the oral administration route and is available in forms such as tablets, capsules, and liquid suspensions. The protocol for its use mandates the principle of using the lowest effective dosage for the shortest duration consistent with treatment goals.

The standard adult dosing for symptomatic management of discomfort typically begins with a single dose between 200 mg and 400 mg. This medication is generally taken on an as-needed basis, with subsequent doses administered every 4 to 6 hours. The maximum recommended total daily intake is 1200 mg for general over-the-counter use, while physician-supervised use may reach 3200 mg when taken in divided doses.

Contextual Administration Requirements include the permission to take the medicine with food or milk to lessen the possibility of gastric upset. If the liquid suspension form is used, it must be shaken well prior to dispensing, and the dose should be accurately measured only with a calibrated device. Population-specific instructions require body weight-based dosing for pediatric patients (children 6 months) and the directive for a minimized dose regimen for older adults. The procedural instruction for handling a missed dose is to skip the forgotten dose and not use two doses together.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action Studies

Early in vitro and animal studies explored the basic function of the drug. The compound's early research examined its role in the inhibition of the COX-2 enzyme pathway. The drug's mechanism is being explored in research focused on pain markers. Further investigation into the drug’s selectivity over COX-1 is ongoing.

Clinical Efficacy in Acute Pain

The drug has been studied as an option for the management of acute pain conditions. Research has evaluated the use in patients with acute pain conditions. Key Phase III trials focused on specific dosage regimens.

  • Primary Outcome Data: A multinational, double-blind, placebo-controlled trial compared its efficacy profile to standard non-steroidal anti-inflammatory drugs (NSAIDs). The primary study evaluated whether it improved patient-reported mobility scores over a two-week period. Evidence from multiple studies evaluated its impact on pain intensity.
  • Dose-Response: Other research has focused on the relationship between dosage and reported analgesic effect, with data evaluating the reduction of pain scores across a 50 mg to 200 mg range.

Pharmacokinetics and Tolerability

Studies have been conducted to understand how the drug is absorbed, metabolized, and eliminated by the body. Research on pharmacokinetics has often focused on specific dose levels for analysis. Specific studies have examined the drug's pharmacokinetic profile in detail. These studies also evaluated the onset of action data.

Combination Therapy Research

Research has also exploratorily evaluated the drug’s potential when used alongside non-pharmacological interventions. Specifically, studies evaluated the impact of the combination on inflammation scores in patients with chronic musculoskeletal conditions compared to the drug alone. Findings were mixed on whether combining the drug with standard physical therapy protocols demonstrated an additional effect on pain severity markers.

Frequently Asked Questions (FAQ)

Common questions about Butifen (FAQ)

Q: Does Butifen cause weight gain?

Regulatory documents state that unusual or sudden weight gain is a potential symptom associated with an adverse reaction called fluid retention (edema). Since this can be a warning sign of a serious event, any unexpected weight gain or swelling of the extremities is typically noted in a patient's records.

Q: Can Butifen affect my sleep?

Official product information lists effects on the central nervous system as possible adverse reactions. These may manifest as feelings of drowsiness or sleepiness. Conversely, some documentation indicates that sleeplessness may also occur.

Q: Is Butifen safe to use during pregnancy?

Official documents state that the medication is absolutely prohibited (contraindicated) starting at 30 weeks of pregnancy, which is the beginning of the third trimester. It is also generally not recommended for use during the first and second trimesters of pregnancy.

Q: Can Butifen affect blood sugar levels?

Changes in blood sugar levels have been mentioned in association with the use of this type of medication, although this is noted as a rare or uncommon effect in regulatory documents. Specifically, low blood sugar (hypoglycemia) is sometimes documented.

Q: Does Butifen contain lactose or gluten?

The active ingredient is Ibuprofen, but the inactive ingredients (excipients), such as lactose or gluten, can vary significantly depending on the specific product form and manufacturer. Because of this variability, patients are generally advised to check the specific ingredients list on the package or the official label for the product being used.

Q: Can I take Butifen every day?

Official over-the-counter labeling and regulatory guidance generally emphasize using the lowest effective amount for the shortest duration possible. Limits are typically recommended, often suggesting use for no more than 10 consecutive days for pain, as using the medication for a longer duration is associated with an increased risk of serious adverse events.

Q: Are there any long-term effects from taking Butifen?

Regulatory agencies emphasize that the risk of serious adverse events may increase with the length of time the medication is used. These serious events include gastrointestinal bleeding and specific cardiovascular thrombotic events, such as heart attack or stroke.

Q: Can Butifen interact with common supplements like vitamin C?

Regulatory interaction statements are created to highlight known risks with other prescription or over-the-counter medicines. These official lists do not typically include specific warnings about common nutritional supplements like Vitamin C.

Q: Is Butifen suitable for people with high blood pressure?

Official labeling includes a specific caution for patients with existing high blood pressure (hypertension). Regulatory documents note that the medication may lead to the onset of new hypertension or the worsening of pre-existing hypertension. Close monitoring is recommended during treatment.

Q: Is it normal to feel a bit dizzy after taking Butifen?

Yes, dizziness is listed in regulatory documents as a potential adverse reaction associated with use. Dizziness is a possible adverse reaction that may be noted in regulatory documentation.

Q: How long do the effects of Butifen usually last?

According to official product information, the therapeutic effects of the drug typically last approximately 4 to 6 hours. This duration aligns with the dosing interval described in administration guidelines for the product.

Q: Can Butifen cause skin sensitivity or rashes?

Regulatory safety documents explicitly list rashes, hives, and other severe skin reactions as potential adverse effects. These effects may be associated with a hypersensitivity reaction to the drug.

Q: What should I know about taking Butifen if I have asthma?

Official documents advise that the medication is prohibited (contraindicated) for use in patients who have experienced asthma or allergic reactions after taking aspirin or other NSAIDs. Regulatory documents also advise caution for all patients with pre-existing asthma.

Q: How quickly is Butifen eliminated from the body?

The active ingredient is quickly processed and removed by the body. Regulatory pharmacokinetics sections define the elimination half-life—the time required for half the drug to be removed—as typically in the range of 1.9 to 2.2 hours.

Q: Is Butifen associated with any cardiovascular concerns?

Regulatory labeling includes a serious warning that the medication is associated with an increased risk of serious cardiovascular thrombotic events. These events include the possibility of heart attack and stroke.

Q: Why is Butifen not suitable for some patients?

Regulatory documents indicate that the medication is not suitable for patients with severe underlying conditions. Reasons for prohibition (contraindications) include a history of hypersensitivity to NSAIDs, active gastrointestinal bleeding or ulcers, severe heart or kidney failure, or being in the third trimester of pregnancy.

Q: Can Butifen be used for pain relief in pets (informational)?

The medication holds official approval solely for human use. Authoritative veterinary resources state that it should not be given to pets, such as dogs, due to a high risk of toxicity and serious adverse health effects.

Q: What if I experience unusual side effects after starting Butifen?

Patient information guides advise that if signs of a serious reaction occur, such as chest pain, trouble breathing, or passing black/tarry stools, the medication should be stopped. Patient information guides describe that seeking immediate medical attention is advisable if these symptoms develop.

Q: What is the shelf life of Butifen tablets?

The specific shelf life or expiration date is determined by the manufacturing process and is required by law to be printed directly on the product's container or packaging. The date listed on the specific product packaging represents the final time point for use.

Q: Do I need to take Butifen with food?

Official administration guidelines state that the medicine may be taken with food or milk. This is often done to help minimize the possibility of stomach upset, but taking it with food is generally not described as a mandatory requirement for its intended physiological action.

Q: Are there different forms of Butifen (e.g., tablet, liquid)?

Yes, regulatory documentation confirms that the medication is officially available in several oral dosage forms. These commonly include tablets, capsules, and liquid suspensions for oral administration.

Q: What kind of studies have been done on Butifen?

Research has been conducted across several key areas. These include studies on its anti-inflammatory mechanism, its efficacy in managing acute pain, its pharmacokinetic profile (how the body processes it), and its tolerability profile in various patient groups.

How should Butifen be stored and disposed of?

Storage Conditions

Butifen (Ibuprofen) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The regulatory labeling permits brief temperature fluctuations between 15 C and 30 C. Liquid formulations, such as the oral suspension, must not be frozen. The medicine must be kept in its original container, and for stability reasons, liquid products should be kept tightly closed.

Child Safety and Stability

It is officially required to keep Butifen out of the sight and reach of children.

Disposal Instructions

Expired or unused Butifen must be disposed of by following local state and federal disposal regulations. Regulatory documents advise that the medicine should not be thrown into wastewater (e.g., down the sink or toilet) or regular household trash, and drug take-back programs should be utilized when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Butifen found in:

A-Z Index: